1. E-selectin inhibitor is superior to low-molecular-weight heparin for the treatment of experimental venous thrombosis
- Author
-
Daniel D. Myers, William E. Fogler, John L. Magnani, Thomas W. Wakefield, Suman L. Sood, Angela E. Hawley, Robert E. Sigler, Laura Durham, Michael Holinstat, Veronica Dunivant, Garrett Reynolds, Kiley Crego, Reheman Adili, Patrick A Lester, and Junjie Ning
- Subjects
medicine.medical_specialty ,medicine.drug_class ,Deep vein ,Urology ,Low molecular weight heparin ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Bleeding time ,medicine ,Animals ,030212 general & internal medicine ,Vein ,Venous Thrombosis ,medicine.diagnostic_test ,business.industry ,Anticoagulants ,Heparin, Low-Molecular-Weight ,medicine.disease ,Thrombosis ,Thromboelastography ,Venous thrombosis ,medicine.anatomical_structure ,Surgery ,Glycolipids ,E-Selectin ,Cardiology and Cardiovascular Medicine ,business ,Papio ,Partial thromboplastin time - Abstract
Background This study evaluated E-selectin inhibition with GMI-1271 (Uproleselan [GMI]) alone and in combination with the standard of care low-molecular-weight heparin (LMWH) to improve vein recanalization, decrease vein wall inflammation and protect against adverse bleeding in a primate model. We sought to examine this novel treatment of venous thrombosis. Methods Using a well-documented primate animal model, iliac vein thrombosis was induced by balloon occlusion of the iliac vein for 6 hours. Starting on day 2 after thrombosis, animals began treatment in two phases. In phase one, nontreated controls received no treatment (n = 5) vs animals treated with the E-selectin inhibitor GMI, 25 mg/kg, subcutaneous (SC), once daily (n = 4) for 21 days (previously published data). In phase two, animals were treated with GMI plus a combination of LMWH 1.5 mg/kg or 40 mg (GMI + LMWHc) SC once daily (n = 8) for 19 days; and animals treated with LMWH 1.5 mg/kg or 40 mg (LMWHc) SC once daily (n = 6) for 19 days. Animals were evaluated by magnetic resonance venography for vein recanalization and inflammation by gadolinium extravasation, duplex ultrasound, coagulation tests (thromboelastography, bleeding time, prothrombin time, activated partial thromboplastin time, fibrinogen) and complete blood count at baseline, days 2, 7, 14, and 21 at euthanasia. Statistical analysis included using unpaired t test with Welch's correction for direct comparisons and one-way analysis of variance for comparison between the groups. Results Percent vein recanalization by magnetic resonance venography was highest in the GMI alone group followed by GMI + LMWHc, both significantly different from control. On ultrasound examination, animals treated with GMI alone had no decrease in open vein lumen by day 21, whereas decreases were observed in groups GMI + LMWHc (–26%), LMWHc (–27%), and controls (–80%). Vein wall inflammation decreased significantly in all treated groups. Intimal fibrosis and intimal thickness was best preserved in the GMI alone group. An analysis of total vein wall collagen revealed a trend in all treatment groups of decreasing vein wall collagen. No clinically significant bleeding events were noted in any group. The LMWH groups trended to have prolonged coagulation test values, whereas E-selectin inhibition with GMI did not cause clinically significant changes in coagulation measures. Conclusions Treatment with E-selectin inhibition results in improved vein recanalization, a decrease in vein wall inflammation and vein wall intimal thickness and fibrosis, with no changes in markers of coagulation. E-selectin inhibition with GMI alone is superior to E-selectin inhibition combined with LMWH, LMWH alone, and no treatment in this deep vein thrombosis model of iliac vein thrombosis.
- Published
- 2022
- Full Text
- View/download PDF